[go: up one dir, main page]

MX2024010165A - Metodos para tratar la miositis mediante el uso de antagonistas de fcrn. - Google Patents

Metodos para tratar la miositis mediante el uso de antagonistas de fcrn.

Info

Publication number
MX2024010165A
MX2024010165A MX2024010165A MX2024010165A MX2024010165A MX 2024010165 A MX2024010165 A MX 2024010165A MX 2024010165 A MX2024010165 A MX 2024010165A MX 2024010165 A MX2024010165 A MX 2024010165A MX 2024010165 A MX2024010165 A MX 2024010165A
Authority
MX
Mexico
Prior art keywords
methods
myositis
fcrn
fcrn antagonists
treating
Prior art date
Application number
MX2024010165A
Other languages
English (en)
Inventor
Der Woning Sebastian Paul Van
Laurent Drouot
Olivier Boyer
Original Assignee
argenx BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by argenx BV filed Critical argenx BV
Publication of MX2024010165A publication Critical patent/MX2024010165A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

En la presente descripción se proporcionan métodos para tratar la miositis mediante el uso de una cantidad eficaz de un antagonista del receptor de Fc neonatal (FcRn) humano. También se proporcionan en la presente descripción antagonistas de FcRn para su uso en el tratamiento de la miositis y para su uso en la fabricación de un medicamento para el tratamiento de la miositis.
MX2024010165A 2022-02-21 2023-02-17 Metodos para tratar la miositis mediante el uso de antagonistas de fcrn. MX2024010165A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263268312P 2022-02-21 2022-02-21
US202263269430P 2022-03-16 2022-03-16
US202263365824P 2022-06-03 2022-06-03
US202263407369P 2022-09-16 2022-09-16
PCT/EP2023/054065 WO2023156614A1 (en) 2022-02-21 2023-02-17 Methods for treating myositis using fcrn antagonists

Publications (1)

Publication Number Publication Date
MX2024010165A true MX2024010165A (es) 2024-08-27

Family

ID=85380794

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024010165A MX2024010165A (es) 2022-02-21 2023-02-17 Metodos para tratar la miositis mediante el uso de antagonistas de fcrn.

Country Status (11)

Country Link
US (1) US20250084171A1 (es)
EP (1) EP4482582A1 (es)
JP (1) JP2025508766A (es)
KR (1) KR20240151809A (es)
CN (1) CN119923273A (es)
AU (1) AU2023221552A1 (es)
CA (1) CA3244139A1 (es)
IL (1) IL315112A (es)
MX (1) MX2024010165A (es)
TW (1) TW202337895A (es)
WO (1) WO2023156614A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020005981A (es) 2017-12-08 2020-08-24 Argenx Bvba Uso de antagonistas del fcrn para el tratamiento de la miastenia gravis generalizada.
CN112513073A (zh) 2018-06-08 2021-03-16 阿根思公司 用于治疗免疫性血小板减少症的组合物和方法
US12403175B2 (en) 2020-01-08 2025-09-02 argenx BV Methods for treating pemphigus disorders
WO2023242372A1 (en) 2022-06-15 2023-12-21 argenx BV Fcrn/hsa binding molecules and methods of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
CA2687117A1 (en) 2007-05-14 2008-11-27 Biogen Idec Ma Inc. Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
KR20220152546A (ko) 2013-12-24 2022-11-16 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 Fcrn 길항제 및 사용방법

Also Published As

Publication number Publication date
AU2023221552A1 (en) 2024-09-05
WO2023156614A1 (en) 2023-08-24
KR20240151809A (ko) 2024-10-18
IL315112A (en) 2024-10-01
TW202337895A (zh) 2023-10-01
EP4482582A1 (en) 2025-01-01
US20250084171A1 (en) 2025-03-13
CA3244139A1 (en) 2023-08-24
JP2025508766A (ja) 2025-04-10
CN119923273A (zh) 2025-05-02

Similar Documents

Publication Publication Date Title
MX2024010165A (es) Metodos para tratar la miositis mediante el uso de antagonistas de fcrn.
MX2024013015A (es) Métodos para tratar penfigoide ampolloso con el uso de antagonistas de fcrn
MX2025008040A (es) Métodos para tratar el síndrome de sjögren primario con el uso de antagonistas fcrn
MX2020008977A (es) Formulaciones de anticuerpos de her2 subcutaneas.
CL2019002470A1 (es) Combinaciones de un derivado de 4-pirimidinsulfamida con ingredientes activos para el tratamiento de enfermedades relacionadas con endotelina.
CL2020000974A1 (es) Tratamiento de la glomerulosclerosis focal y segmentaria con anatagonistas ccr2.
BR112021010354A2 (pt) Métodos para o tratamento usando terapia celular adotiva
UY38263A (es) Compuestos de purinona y su uso en el tratamiento del cáncer
MX2021005024A (es) Metodos de tratamiento que utilizan receptores de antigenos quimericos especificos para antigeno de maduracion de celulas b.
MX2019011117A (es) Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos.
MX2020009773A (es) Terapia de combinacion.
AR131560A1 (es) Métodos para tratar pots mediante el uso de antagonistas de fcrn
MX2025005240A (es) Métodos para el tratamiento de la nefritis lúpica mediante el uso de antagonistas de fcrn
MX2021002556A (es) Tratamiento del dolor postquirurgico.
CO2020014599A2 (es) Métodos para tratar cáncer
MX376312B (es) Uso de antagonistas del receptor ep4 para el tratamiento de cancer de higado asociado con nash
CL2022002813A1 (es) Semaglutida para el tratamiento de esteatohepatitis no alcoholica.
CO2022010592A2 (es) Métodos de tratamiento de la esplenomegalia
MX2021014161A (es) Metodos de tratamiento del sindrome de sjogren utilizando un inhibidor de la tirosina quinasa de bruton.
MX2023002087A (es) Agonistas del receptor crf2 y su uso en terapia.
CL2020000270A1 (es) Combinación terapéutica de un inhibidor tirosina quinasa del egfr de tercera generación y un inhibidor raf.
CO2023008676A2 (es) Compuestos polipéptidos modificados con lactama
CO2022006466A2 (es) Inhibidores de egfr alostéricos y métodos de uso de los mismos
PH12021551805A1 (en) Treatment of skin lesions and pruritus in prurigo nodularis patients
MX2022016406A (es) Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un inhibidor de hif-2 alpha y lenvatinib.